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Objectives. We sought to document the common mechanisms of
the antiatherogenic effects of the cholesterol-lowering hydroxy-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor lova-
statin, the dihydropyridine Ca21 blocker amlodipine and the
antioxidant vitamin E.
Background. Vitamin E, HMG-CoA reductase inhibitors and
Ca21 blockers each inhibit atherosclerosis in hypercholester-
olemic animals.
Methods. New Zealand White rabbits were fed regular chow
(Group A), chow with 1% cholesterol (Group B), 1% cholesterol
diet plus lovastatin (Group C), 1% cholesterol diet plus vitamin E
(Group D) or 1% cholesterol diet plus amlodipine (Group E) for
12 weeks. The extent of aortic atherosclerosis was measured by
planimetry of the sudanophilic area. Malondialdehyde (MDA)
and superoxide dismutase (SOD) in blood were measured as
indexes of lipid peroxidation and antioxidant activity, respec-
tively.
Results. Group A rabbits showed no atherosclerosis, whereas
Group B rabbits had 17.4 6 9.3% (mean 6 SD) of the aorta
covered with atherosclerosis, and Groups C, D and E rabbits had
significantly less atherosclerosis. Plasma SOD activity was lower
in Group B than in Group A (6.9 6 1.1 vs. 12.8 6 1.5 U/ml, p <
0.01) and was preserved in the groups given lovastatin, vitamin E
or amlodipine with a high cholesterol diet. The serum MDA level
was higher in Group B rabbits than Group A rabbits (12.1 6 2.6
vs. 1.2 6 0.1 nmol/ml, p < 0.01) and increased minimally in
rabbits given lovastatin, vitamin E or amlodipine with a high
cholesterol diet. In in vitro experiments, both lovastatin and
amlodipine preserved SOD activity and reduced the oxidizability
of low density lipoproteins by rabbit leukocytes.
Conclusions. This study suggests that a reduction in lipid
peroxidation and preservation of SOD may be common mecha-
nisms of antiatherosclerotic effects of lovastatin, vitamin E and
amlodipine.
(J Am Coll Cardiol 1997;30:569–75)
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Elevated levels of total cholesterol and low density lipoproteins
(LDL) in plasma are major risk factors for the development of
atherosclerosis (1). Much evidence provides support for the
concept that the oxidized form of LDL causes oxidant stress
and increases intracellular Ca21 in the vessel wall, and repre-
sents the pathogenic element in hypercholesterolemia (2,3).
Release of oxidant species from activated leukocytes, such as
superoxide radical and hydroxyl radical, in principle, contrib-
utes to the oxidation of LDL (4). Thus, a strategy directed at
the use of antioxidants such as vitamin E has been advocated
to decrease the susceptibility of LDL to oxidation by interrupt-
ing free radical peroxidative chain reactions (5) and to increase
the resistance to atherosclerosis by protecting against endothe-
lial dysfunction in cholesterol-fed animals (6,7).
Hydroxymethylglutaryl coenzyme A (HMG-CoA) reduc-
tase inhibitors and Ca21 blockers have been shown to prevent
or retard the progression of atherosclerosis (8–11). The classic
HMG-CoA reductase inhibitor, lovastatin, has been found to
inhibit the oxidation of LDL in in vivo and in vitro studies (12).
The calcium antagonists, including lacidipine and cinnarizine,
have been reported to inhibit lipid peroxidation, probably by
quenching several radical species (13,14). So far, the mecha-
nism(s) by which HMG-CoA reductase inhibitors and Ca21
antagonists inhibit oxidation is unclear. It may be hypothesized
that the antiatherogenic effect of these drugs may relate in part
to their ability to limit oxidation of LDL. Notably, the direct
effect of these agents on the endogenous antioxidant system,
such as superoxide dismutase (SOD) (15), has not yet been
well characterized.
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The objective of the present study was to document the
antiatherogenic effects of the cholesterol-lowering HMG-CoA
reductase inhibitor lovastatin, the dihydropyridine Ca21
blocker amlodipine and the well known antioxidant vitamin E.
We used the hypercholesterolemic rabbit as a model for
experimental atherosclerosis. The effects of these agents on
lipid peroxidation and on the endogenous antioxidant system
were assessed in these rabbits. To further study the antioxidant
mechanism(s), the effects of lovastatin and amlodipine on LDL
oxidation mediated by CuSO4 or leukocytes were also investi-
gated. In addition, we examined if a relation exists between the
extent of atherosclerosis and lipid peroxidation and endoge-
nous antioxidant defense.
Methods
This study was approved by the University of Florida and
complied with all local, state and federal guidelines.
Drugs. Lovastatin was obtained from Merck and Co. Am-
lodipine besylate was obtained from Pfizer Laboratories. Vita-
min E (dl-alpha-tocopherol acetate in a base of vegetable oil)
was obtained from Nature’s Bounty. All other chemicals were
purchased from Sigma Chemical Co.
Feeding protocol. New Zealand White rabbits (all males,
starting age 4 to 6 weeks) were randomly assigned to one of the
five dietary groups for 12 weeks: Group A 5 regular chow (n 5
4); Group B 5 regular chow with 1% cholesterol (n 5 6);
Group C 5 high cholesterol diet plus lovastatin, 2 mg/kg body
weight per day (n 5 4); Group D 5 high cholesterol diet plus
vitamin E, 0.04 g/kg per day (n 5 4); Group E 5 high
cholesterol diet plus amlodipine, 2 mg/kg per day (n 5 5).
These diets were prepared by mixing lovastatin, amlodipine
and vitamin E directly into regular chow containing a high
cholesterol diet. The complete consumption of chow was
checked daily to assure that the rabbits had completely con-
sumed their food (;100 g).
Blood and aortic tissue collections. Blood was collected
from an ear vein before the dietary feeding was started. Blood
was collected again at 12 weeks of dietary intervention from
the carotid artery before the rabbits were killed by administra-
tion of sodium pentobarbital (100 mg/kg) into the marginal ear
vein. The aorta was isolated along its entire length, removed
and washed in saline for measurement of the area of sudano-
philia as index of atherosclerosis. Blood was used for measure-
ment of serum cholesterol, malondialdehyde (MDA) and
vitamin E levels and plasma or leukocyte SOD activity.
Quantification of area of atherosclerosis. After fixation,
the lumen surface of the aorta from all the rabbits was stained
with Sudan III/IV solution (prepared by dissolving 1 g of Sudan
III in 100 ml of 70% ethanol and 0.1 g of Sudan IV in 100 ml
of 70% ethanol/acetone and mixing Sudan III and IV). After
washing with water for 5 min, the total and fatty streak surface
areas were quantified by use of computerized planimetry and
recorded. The area of atherosclerosis was expressed as percent
total aortic area.
Determination of serum MDA, cholesterol and vitamin E
levels. Malondialdehyde in serum was determined by a mod-
ification of the method of Ohkawa et al. (16). The assay
mixture consisted of 0.1 ml of the serum, 0.4 ml of 0.9% NaCl,
0.5 ml of 3% sodium dodecylsulfate, 3 ml of thiobarbituric acid
reagent (containing equal parts of 0.8% aqueous thiobarbituric
acid and acetic acid) and was heated for 75 min at 95°C.
Thereafter, the mixture was added to 1 ml of cold 0.9% NaCl
and cooled in tap water and extracted by adding 5 ml of
n-butanol. After centrifugation at 3,000 rpm for 15 min, the
butanol phase was assayed spectrophotometrically at 532 nm.
Amounts of 0, 20, 40, 60 and 80 nmol of tetramethoxypropane
served as the external standard and were assayed in the
previously described fashion. Serum MDA content was ex-
pressed as nmol/ml. Serum cholesterol was estimated by use of
a routine automated system. Plasma vitamin E (alpha-, beta-
and gamma-tocopherol) was measured by high performance
liquid chromatography with fluorescence detection, as de-
scribed earlier (17).
Determination of SOD activity. Total SOD activity in
plasma was measured spectrophotometrically by monitoring
the SOD-inhibitable autoxidation of pyrogallol, as described by
Marklund and Marklund (18). The reaction mixture (4.5 ml)
contained 0.2 mmol/liter of pyrogallol, 1 mmol/liter of dieth-
ylenetriamine pentaacetic acid, 50 mmol/liter of Tris-cacodylic
acid buffer (pH 8.2) and 4 mg of catalase. The reaction was
carried out at 25°C. The rate of increase in absorbance at
420 nm was recorded. One unit of enzyme activity is defined as
50% inhibition of pyrogallol autoxidation under the assay
conditions. The SOD activity in plasma is expressed as units
per milliliter.
Preparation of leukocytes. Rabbit leukocytes were isolated
using the method described by Chand et al. (19). Briefly, about
30 ml of blood from the carotid artery was collected in 3.8%
sodium citrate and mixed with 7.5 ml of 6% dextran in isotonic
saline and allowed to stand for 30 min at 37°C. The leukocyte-
rich upper layer was transferred to another tube containing
2.25 ml of 0.1 mol/liter of EDTA and centrifuged at 1,000 rpm
at 4°C. The leukocytes were washed with Tris buffer (compo-
sition in mmol/liter: Tris, 25; NaCl, 120; KCl, 5; bovine
albumin, 0.03%; and dextrose, 0.1%) with or without
0.6 mmol/liter of CaCl2 and 1 mmol/liter of MgCl2 at 4°C.
Lovastatin, amlodipine and LDL oxidation. To investigate
the effect of lovastatin on copper- or leukocyte-mediated LDL
oxidation, LDL (50 mg/ml) was incubated with CuSO4
Abbreviations and Acronyms
Ca21 5 calcium
CuSO4 5 copper sulfate
HMG-CoA 5 hydroxymethylglutaryl coenzyme A
LDL 5 low density lipoprotein
MDA 5 malondialdehyde
PMA 5 phorbol 12-myristate 13-acetate
SOD 5 superoxide dismutase
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(10 mmol/liter) or phorbol 12-myristate 13-acetate (PMA,
100 ng/ml)–stimulated rabbit leukocytes (106 cells/ml) in 2 ml
of Tyrode’s buffer (composition in mmol/liter: NaCl, 137; KCl,
2.7; MgCl2, 1.0; CaCl2, 1.0; NaH2PO4, 0.35; NaHCO3, 11.9;
and glucose, 5.5 at pH 6.5) with or without different concen-
trations of lovastatin (5 and 10 mmol/liter) or amlodipine (50
and 100 mg/ml) at 37°C. After 1 h of incubation, leukocytes
were centrifuged and used to measure SOD activity with the
method described earlier. The kinetics of LDL oxidation in the
aliquots of supernate were determined by monitoring the
change in absorbance (234 nm) on a Perkin-Elmer lambda 5
UV-spectrophotometer. Absorbance was recorded every hour
for 6 h. From the kinetic absorbance profile of each experi-
ment, the maximal rate of oxidation was calculated from the
slope of the absorbance curve during the propagation phase,
expressed as nmol dienes/min per mg LDL protein. Superoxide
dismutase activity in leukocytes treated as described previously
was measured and expressed as U/2 3 106 cells.
Statistics. All data are presented as mean value 6 SD.
Comparison among different groups was made by analysis of
variance followed by the Student-Newman-Keuls test. Corre-
lation between MDA and SOD values and extent of sudano-
philia was made by stepwise linear regression analysis using the
Statview version 4.2 program.
Results
Body weight and feed intake. There was no significant
difference in body weight among the different groups of
rabbits. No difference in food intake was observed, as all
rabbits completely finished their rations every day.
Atheromatous fatty streak formation. Representative ex-
amples of the areas of atherosclerosis are presented in Figure
1. Group A rabbits fed regular chow for 12 weeks showed no
visible atherosclerosis lesions in all the aortas. In Group B
rabbits, fatty streaks covered 17.4 6 9.3% of the aortic area.
However, the extent of atherosclerosis was significantly de-
creased in rabbits fed a high cholesterol diet with either
lovastatin, vitamin E or amlodipine (extent of atherosclerosis
as percent aortic area 5.3 6 0.7%, 9.7 6 1.7% and 10.2 6
4.2%, respectively, all p , 0.05 vs. Group B).
Serum MDA, cholesterol and vitamin E levels and plasma
SOD activity. The mean serum MDA level was increased
;10-fold in Group B rabbits compared with Group A rabbits
(12.1 6 2.6 vs. 1.2 6 0.1 nmol/ml, p , 0.01). The increase in
serum MDA was significantly (p , 0.05) reduced by supple-
mentation of a cholesterol-rich diet with lovastatin, vitamin E
or amlodipine (Table 1).
The average baseline serum cholesterol level in Group A
rabbits was 60 6 17 mg/dl. Serum cholesterol levels were
significantly greater in rabbits fed high cholesterol, whether or
not supplemented with lovastatin, vitamin E or amlodipine
(Table 1).
The baseline serum vitamin E level was 1.96 6 0.19 mg/ml
in Group A and remained unchanged with feeding of regular
chow. Serum vitamin E levels were significantly increased in all
rabbits fed a high cholesterol diet. As expected, a high
cholesterol diet supplemented with vitamin E caused a further
increase (27.2 6 7.7 vs. 8.4 6 0.01 mg/ml in Group B, p , 0.01)
(Table 1).
Plasma SOD activity was markedly decreased in rabbits fed
a high cholesterol diet (6.9 6 1.1 vs. 12.8 6 1.5 U/ml plasma in
Group A, p , 0.01). Treatment with lovastatin, vitamin E or
amlodipine increased and preserved SOD activity despite
intake of a high cholesterol diet (Table 1).
Effect of lovastatin or amlodipine on oxidation of LDL and
leukocyte SOD activity. Copper sulfate (CuSO4) or leukocyte-
induced oxidation was quantitated by continuously monitoring
the conjugated diene formation, and the oxidizability of LDL
was expressed as the maximal rate of oxidation. Treatment
with 5 mmol/liter of lovastatin significantly decreased the
maximal rate of oxidation induced by leukocytes from 2.2 6
0.1 to 1.2 6 0.3 nmol dienes/min per mg LDL protein, and
Figure 1. Examples of sudanophilic areas in the aorta from different
groups. Rabbits were fed regular chow (control diet) or chow with a
high cholesterol diet alone or with lovastatin, vitamin E or amlodipine
for 12 weeks. Although feeding the rabbits a high cholesterol diet
resulted in large areas of sudanophilia, concurrent administration of
lovastatin, vitamin E and amlodipine each resulted in a marked
reduction in the areas of sudanophilia.
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10 mmol/liter of lovastatin totally blocked the initiation of LDL
oxidation induced by leukocytes. Amlodipine also decreased
the oxidizability of LDL mediated by leukocytes, but to a lesser
extent. Results of representative experiments are shown in
Figures 2 and 3, and the results from four experiments are
summarized in Table 2. Neither lovastatin nor amlodipine
affected CuSO4 (10 mmol/liter)–induced oxidation of LDL
(data not shown).
Superoxide dismutase activity was significantly preserved by
both lovastatin and amlodipine in PMA-stimulated leukocytes.
Interestingly, SOD activity was preserved in the presence of
LDL, and it increased further in the presence of lovastatin or
amlodipine in PMA-stimulated leukocytes. The results are
summarized in Table 2.
Extent of atherosclerosis, serum MDA level and plasma
SOD activity. There was a linear relation between the extent
of atherosclerosis and serum MDA level (y 5 3.143x 2 7.4224,
r 5 0.866, n 5 23). There was an insignificant inverse relation
between plasma SOD activity and the extent of atherosclerosis.
A similar absence of relation was found between plasma SOD
and serum MDA levels.
Discussion
Lipid peroxidation, antioxidant activity and atherosclero-
sis. The causative role of increased cholesterol level and lipid
peroxidation in the development of atherosclerosis (1), as well
as in the antiatherogenic effects of HMG-CoA reductase
inhibitors, Ca21 blockers and antioxidants, has been well
documented (5–11). This study, for the first time, provides
definitive evidence that the extent of atherosclerosis is propor-
tional to the extent of lipid peroxidation. In support of this
concept, we found a positive correlation between the extent of
aortic atherosclerosis and plasma MDA values. We also found
that lovastatin, amlodipine and vitamin E each protected
against lipid peroxidation and preserved the endogenous anti-
oxidant enzyme SOD in hyperlipidemic rabbits. In addition, we
demonstrated the antioxidant activity of both lovastatin and
amlodipine, by their inhibitory effects on the oxidation of LDL
in in vitro experiments.
The presence of lipid peroxides in tissue and cell lipids has
long been assumed to be a sign of atherosclerosis (20). Despite
the presence of potent antioxidant defenses in plasma, there
are detectable levels of lipid peroxides in plasma in atheroscle-
rosis (21–24). The present study extended these previous
observations. We found that the increased lipid peroxidation
was associated with decreased activity of the endogenous
antioxidant enzyme SOD, but there was no direct correlation
between the degree of lipid peroxidation and loss of antioxi-
dant activity. Furthermore, there was no significant correlation
between SOD activity and the extent of atherosclerosis. These
observations, nonetheless, provide evidence that increased
oxidative stress or decreased antioxidant activity, or both, are
major mechanism(s) involved in the pathogenesis of athero-
sclerosis (25). These data may also be taken to affirm the view
that plasma lipid peroxidation is a consequence of the athero-
sclerosis process.
The weak correlation between plasma SOD activity and
atherosclerosis may reflect the presence of multiple antioxi-
dants, of which SOD is only one component. The levels of
different antioxidants may vary during atherogenesis. Superox-
ide dismutase activity, perhaps the most important antioxidant
enzyme (15), fell in our study, whereas the levels of vitamin E,
the most abundant naturally occurring lipid-soluble antioxi-
dant, increased in all rabbits fed a high cholesterol diet. The
precise mechanism of increased levels of vitamin E in plasma
in these rabbits is not clear; however, it has been reported that
LDL isolated from plasma contains considerable amounts of
antioxidants, such as vitamin E and carotenoids (26). Because
vitamin E is predominantly associated with LDL, its increased
levels in hypercholesterolemic animals may simply reflect
elevated plasma lipid levels. The pathophysiologic significance
of this phenomenon remains unclear. It may be speculated that
the increased vitamin E level in plasma may affect SOD
measurement, resulting in an increased level of the latter.
Figure 2. Effect of lovastatin on oxidizability of LDL by rabbit
leukocytes. The 5-mmol/liter concentration of lovastatin reduced the
oxidizability, whereas 10 mmol/liter totally blocked the process. This
experiment is representative of four similar experiments.
Table 1. Effects of Lovastatin, Vitamin E and Amlodipine on Serum
Malondialdehyde, Cholesterol, Vitamin E and Plasma Superoxide
Dismutase Activity in High Cholesterol–Fed Rabbits
MDA
(nmol/ml)
Cholesterol
(mg/dl)
Vitamin E
(mg/ml)
SOD
Activity
(U/ml)
Group A 1.2 6 0.1 60 6 17 1.96 6 0.19 12.8 6 1.5
Group B 12.1 6 2.6* 632 6 121* 8.40 6 0.01* 6.9 6 1.1*
Group C 4.2 6 0.6† 630 6 121* 4.80 6 0.04* 9.5 6 0.8†
Group D 2.5 6 0.9† 836 6 112* 27.20 6 7.70§ 20.4 6 4.5†
Group E 6.5 6 0.7† 1,270 6 257* — 11.4 6 4.0†
*p , 0.01 versus group A. †p , 0.05 versus group B. §p , 0.01 versus group
A, B or C. Data are presented as mean value 6 SD. Group A 5 regular chow
only; Group B 5 high cholesterol diet alone; Group C 5high cholesterol diet
plus lovastatin; Group D 5high cholesterol diet plus vitamin E; Group E 5high
cholesterol diet plus amlodipine; MDA 5 malondialdehyde; SOD 5 superoxide
dismutase.
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However, we found that SOD activity was significantly de-
creased in Group B rabbits, whereas the plasma vitamin E level
was increased. We therefore believe that a high vitamin E level
in the blood is unlikely to be the sole basis of preservation of
antioxidant activity in Group C, D and E rabbits.
Calcium blockers, statins and lipid peroxidation. The
proximity of the endothelium to circulating leukocytes makes it
an important early target for leukocyte adherence (27). The
activation of leukocytes can damage the vascular tissues by
release of free radicals and proteolytic enzymes. Superoxide
radicals from activated leukocytes adherent to the blood
vessels have been recognized as an initiating factor in the
oxidation of LDL (4). Thus, lipid peroxidation is evident at all
stages of atherosclerosis, especially in early atherosclerotic
lesions (28). It has been suggested that antioxidants exert their
greatest beneficial effect on early lesions (25). Epidemiologic
evidence and clinical trials have suggested that vitamin E may
slow the atherogenic process and prevent nonfatal myocardial
infarction in patients with coronary artery disease (29,30).
Similar to vitamin E, clinical trials and angiographic studies
have demonstrated that statins and Ca21 blockers significantly
decrease the frequency of cardiac events and the number of
new atherosclerotic lesions (31–33). However, so far it is
uncertain as to how statins and Ca21 blockers have an effect
similar to that of vitamin E. In the present study, supplemen-
tation with vitamin E was found to further increase plasma
vitamin E levels and decrease lipid peroxidation by increasing
endogenous SOD activity in rabbits fed a high cholesterol diet.
Importantly, lovastatin and amlodipine also significantly de-
creased plasma lipid peroxides and preserved plasma SOD
activity. Our in vitro study also shows that SOD activity in
PMA-activated leukocytes is significantly increased by both
lovastatin and amlodipine, indicating that the antiatherogenic
effect of these three agents may be, at least in part, mediated
through a common antioxidant pathway.
Lovastatin, an HMG-CoA reductase inhibitor, is known for
its potent LDL cholesterol-lowering effect (8,9). Interestingly,
in the present study, lovastatin had no significant effect on
plasma cholesterol levels, perhaps because the dose used in the
present study may have been too low (34) and the cholesterol
load too high, and yet it reduced the extent of aortic athero-
sclerosis. Similar to our study, Saitoh et al. examined the effect
of fenofibrate in hyperlipidemic rabbits and found an antiathe-
romatous effect independent of the hypolipidemic effect of this
agent (35).
The clinically relevant dose of lovastatin used in our study
might act as an antioxidant in this atherosclerotic model (12)
and exert an antiatherosclerotic effect. In our in vitro studies,
we observed that lovastatin at a high concentration abolished
PMA-activated leukocyte-induced oxidation of LDL. This an-
tioxidant effect of lovastatin was associated with an increase in
SOD activity in rabbit leukocytes. The lovastatin molecule, per
se, does not contain an antioxidant center. However, by
inhibiting the isoprenoid reaction during the activation of
NADPH oxidase, lovastatin may affect the generation of
oxygen radicals (36). Indeed, lovastatin and a related com-
pound, simvastatin, have been reported to inhibit LDL oxida-
tion induced by activated macrophages by reducing superoxide
production (12,37).
It is noteworthy that SOD activity in PMA-activated rabbit
Figure 3. Effect of amlodipine on oxidizability of LDL by
rabbit leukocytes. The 50-mg/ml concentration of amlodipine
reduced the oxidizability, whereas 100 mg/ml further reduced
the process. This experiment is representative of four similar
experiments.
Table 2. Effects of Lovastatin and Amlodipine on Low Density
Lipoprotein Oxidation Induced by Leukocytes and on Superoxide
Dismutase Activity in Leukocytes
Oxidation Rate
(nmol dienes/min
per mg LDL
protein)
SOD Activity
(U/2 3 106 cells)
Leukocytes alone 0 0.11 6 0.03
Leukocytes plus PMA 0 0.08 6 0.02
LDL plus leukocytes plus PMA 2.2 6 0.1 0.11 6 0.03
LDL plus leukocytes plus PMA plus
5 mmol/liter of lovastatin
1.2 6 0.3* 0.17 6 0.04*
LDL plus leukocytes plus PMA plus
10 mmol/liter of lovastatin
0* 0.25 6 0.06*
LDL plus leukocytes plus PMA plus
50 mg/ml of amlodipine
1.5 6 0.4* 0.19 6 0.06*
LDL plus leukocytes plus PMA plus
100 mg/ml of amlodipine
1.3 6 0.3* 0.26 6 0.08*
*p , 0.05 versus LDL plus leukocytes plus PMA. Data are presented as
mean value 6 SD. LDL 5 low density lipoprotein; PMA 5 phorbol 12-myristate
13-acetate; SOD 5 superoxide dismutase.
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leukocytes was also preserved in the presence of LDL. This
effect of LDL may be related to its large amounts of antioxi-
dant components such as vitamin E, which can act as the
scavengers of free radicals (25). In addition, LDL serves as a
target of superoxide anion in this system (38).
Like lovastatin, treatment of rabbits with amlodipine also
resulted in a marked increase in antioxidant activity. Amlodip-
ine is a long-acting dihydropyridine Ca21 antagonist with
vascular selectivity. In vitro studies have suggested that the
dihydropyridine Ca21 antagonists act as antioxidants by di-
rectly quenching several radicals species (13,39). The antioxi-
dant activity of these Ca21 antagonists probably contributes to
their Ca21 blocking effect (40). Our in vitro studies also
demonstrate that amlodipine reduces the oxidizability of LDL
rabbit leukocytes. The studies provide strong evidence that the
antioxidant activity of amlodipine, both in vivo and in vitro,
may relate to the antiatherosclerotic effect of this agent.
Neither lovastatin nor amlodipine had any significant effect
on CuSO4-induced LDL oxidation in vitro, but both agents
reduced leukocyte-induced oxidation of LDL. Notably, the
leukocyte-induced oxidation of LDL depends on the ability of
myeloperoxidase to generate free radicals that oxidize LDL. In
fact, this model of oxidizability of LDL is similar to the in vivo
conditions, because the concentration of free copper or iron,
the most effective ions in the oxidation of LDL, is extremely
low in the body. Our observations of the antioxidant effect of
lovastatin or amlodipine appear to be related to their inhibi-
tory effect on free radical generation from leukocytes and
other tissues.
Conclusions. We have shown an association between in-
creased cholesterol levels and lipid peroxidation in the devel-
opment of atherosclerosis, and we have documented the
antiatherogenic effects of lovastatin, amlodipine and vitamin E
in an atherosclerotic rabbit model. We have also demonstrated
the antioxidant effect of lovastatin and amlodipine both in vivo
and in vitro, and their antioxidant effects were comparable to
the reference antioxidant, vitamin E. This study provides
evidence that the extent of atherosclerosis is proportional to
the extent of lipid peroxidation and that oxidative stress is
increased in the atherosclerotic process. The antioxidant effect
of lovastatin, amlodipine and vitamin E may be a common
mechanism underlying their antiatherosclerotic effect.
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